Gedeon Richter
Gedeon Richter Plc, commonly referred to as Richter, is a prominent global pharmaceutical company headquartered in Hungary (HU). Founded in 1901, the company has established a strong presence in various operational regions, including Europe, Asia, and North America. Specialising in women's health, central nervous system disorders, and generic pharmaceuticals, Richter is renowned for its innovative approach to drug development. The company’s core products include hormonal contraceptives and treatments for infertility, which are distinguished by their high quality and efficacy. Over the years, Gedeon Richter has achieved significant milestones, including strategic partnerships and a robust pipeline of new therapies. With a commitment to research and development, Richter has solidified its position as a key player in the global pharmaceutical market, recognised for its contributions to healthcare and patient well-being.
DitchCarbon Score
How does Gedeon Richter's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gedeon Richter's score of 64 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gedeon Richter's reported carbon emissions
In 2024, Gedeon Richter reported total carbon emissions of approximately 324,127,000 kg CO2e. This figure includes Scope 1 emissions of about 45,632,000 kg CO2e, Scope 2 emissions of approximately 91,724,000 kg CO2e (market-based), and Scope 3 emissions of around 186,771,000 kg CO2e. In 2023, their global emissions were about 336,516,000 kg CO2e, with Scope 1 at 53,104,000 kg CO2e, Scope 2 at approximately 103,252,000 kg CO2e (market-based), and Scope 3 at around 180,160,000 kg CO2e. Gedeon Richter has set ambitious climate commitments, aiming for a 55% reduction in greenhouse gas emissions across all scopes by 2030, starting from a 2020 baseline. Specifically, they plan to reduce Scope 1 emissions by 30% and Scope 2 emissions by 30% by 2030. Additionally, they aim to bring Scope 1 and Scope 2 emissions close to zero by 2025. These initiatives reflect Gedeon Richter's commitment to sustainability and their proactive approach to addressing climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 37,359,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 73,452,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 104,973,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gedeon Richter is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
